Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BEYONDSPRING INC.

(BYSI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BeyondSpring Shares Plummet After FDA Rejects Plinabulin

12/01/2021 | 10:50am EST

By Colin Kellaher

Shares of BeyondSpring Inc. lost more than half of their value Wednesday after the U.S. Food and Drug Administration turned away the company's application seeking approval of its lead asset plinabulin to combat a dose-limiting toxicity related to chemotherapy.

The New York biopharmaceutical company, which was seeking approval of plinabulin in combination with granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia, said the FDA determined that a second study would be needed to support the proposed indication.

BeyondSpring shares were recently changing hands at $6.07, down 53%, after hitting a 52-week low of $5.50 earlier in the session. The stock is more than 80% down from the 52-week intraday high of $33 it hit on Aug. 31.

Analysts at H.C. Wainwright said they were surprised by the rejection, given that BeyondSpring had received breakthrough-therapy designation for plinabulin in the indication and priority review for the application.

H.C. Wainwright cut its recommendation on BeyondSpring shares to neutral from buy and removed its $65 price target, saying the requirement of a second study puts its investment thesis on hold.

BeyondSpring said it is confident in its efficacy and safety data for plinabulin, and that it plans to work closely with the FDA on a future clinical pathway, which may include a second study.

H.C. Wainwright said it believes BeyondSpring remains cash-strong for any future business development decisions, and that the chemotherapy-induced neutropenia program is an "attractive, significantly derisked asset for potential suitors."

BeyondSpring is also studying plinabulin in combination with docetaxel in certain patients with non-small cell lung cancer.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

12-01-21 1049ET

All news about BEYONDSPRING INC.
01/11BEYONDSPRING : Announces Organizational Streamlining - Form 6-K
PU
01/11BeyondSpring to Reduce US Workforce by 35% to Cut Costs
MT
01/11BeyondSpring Announces Organizational Streamlining
GL
01/11BeyondSpring Pharmaceuticals Announces Organizational Streamlining
CI
01/04NORTH AMERICAN MORNING BRIEFING : Stocks to Extend -2-
DJ
01/03BEYONDSPRING : Corporate Presentation
PU
2021BEYONDSPRING : Announces Third Quarter 2021 Financial Results and Provides a Corporate Upd..
PU
2021Earnings Flash (BYSI) BEYONDSPRING Reports Q3 Revenue $337,000
MT
2021BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Up..
GL
2021BeyondSpring Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
More news
Analyst Recommendations on BEYONDSPRING INC.
More recommendations
Financials (USD)
Sales 2021 8,57 M - -
Net income 2021 -64,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,35x
Yield 2021 -
Capitalization 152 M 152 M -
Capi. / Sales 2021 17,7x
Capi. / Sales 2022 12,5x
Nbr of Employees 91
Free-Float -
Chart BEYONDSPRING INC.
Duration : Period :
BeyondSpring Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEYONDSPRING INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 3,88 $
Average target price 11,50 $
Spread / Average Target 196%
EPS Revisions
Managers and Directors
Lan Huang Chairman & Chief Executive Officer
Elizabeth Adkins Czerepak Chief Financial Officer
Ramon W. Mohanlal Director, Chief Medical Officer, Executive VP-R&D
G. Kenneth Lloyd Chief Scientific Officer
Richard J. Daly Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BEYONDSPRING INC.-14.35%152
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.73%52 722
BIONTECH SE-23.97%47 338